骨质疏松症患者骨代谢指标检测的临床价值  

Clinical significance of the determination of bone biochemical metabolic markers in osteoporosis

作　　者：贾海英[1] 木克代斯·米尔地洋[1] 马慧霞[1] 任江林[1] 田永芳[1] 

机构地区：[1]新疆维吾尔自治区人民医院检验科,新疆维吾尔自治区乌鲁木齐830001

出　　处：《中国基层医药》2012年第9期1312-1313,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的研究骨代谢指标在骨质疏松症患者中的变化，探讨各检测指标的临床应用价值。方法应用x线双能骨密度测定仪（DEXA）测定受试者腰椎L2-4。骨密度（BMD），采用酶联免疫法（ELISA）检测65例骨质疏松症患者及62例对照者的骨代谢指标。结果骨质疏松症患者骨代谢指标中TRACP5b、25-OH-VD3/25，-OH-VD：与对照组差异有统计学意义（P〈0．05）；BGP、BAP及血清钙与对照组比较有不同程度的升高，血清磷与对照组比有稍微下降。结论TRACP5b、BGP、BAP、VD。等骨代谢指标可作为骨质疏松的早期检测指标，为骨质疏松的早期用药提供有价值的数据。Objective To evaluate the clinical significance of bone biochemical metabolic markers in osteo- porosis（OP） ,and investigate the clinical application value of the determination. Methods BMD at various skeletal sites was measured by XR-36 dual energy X-ray absorptiometry for 65 patients. Enzyme linked immunosorbent assay （ELISA） were used to determine bone biochemical metabolic markers in sera of 65 patients with osteoporosis and 62 healthy controls. Results The levels of serum TRACP5b and 25-OH-VD3/25-OH-VDz in OP group were higher than that in control group（ P 〈0.05 ） ,meanwhile the level of BGP, BAP and Ca were varying degrees higher than that in control group, but the level of P was lower than that in control group. Conclusion TRACP5b, BGP, BAP, VD3/2 and other bone metabolic markers can be used as indicators of early detection of osteoporosis,in order to provide valuable data for early treatment of osteoporosis.

关 键 词：骨 代谢 骨质疏松症 

分 类 号：R580[医药卫生—内分泌]